400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
2019-06-24
FDA-2015-D-1163
指导原则
美国
现行有效
/
美国食品药品监督管理局(FDA)
GUIDANCE DOCUMENT
This guidance pertains to submissions of promotional materials for human prescription drugs (drugs) to the Food and Drug Administration (FDA or Agency) made by manufacturers, packers, and distributors (firms), whether the applicant or an entity acting on behalf of the applicant. Specifically, this guidance pertains to submissions made to the Office of Prescription Drug Promotion (OPDP) in the Center for Drug Evaluation and Research (CDER) and the Advertising and Promotional Labeling Branch (APLB) in the Center for Biologics Evaluation and Research (CBER). This guidance also explains certain aspects of electronic submission of promotional materials in module 1 of the electronic common technical document (eCTD), using version 3.3 or higher of the us-regional-backbone file.
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2015-D-1163.
摩熵医械2025-11-28
摩熵医械2025-11-17
赛柏蓝2025-11-14
摩熵医械2025-11-12
赛柏蓝2025-11-12
CHC医疗传媒2025-10-30
赛柏蓝2025-10-29
赛柏蓝2025-10-28
赛柏蓝2025-10-24
赛柏蓝2025-10-24
2025-12-01
2025-11-27
2025-11-26
2025-11-24
2025-11-24
2025-11-21
2025-11-18
2025-11-18
2025-11-17
2025-11-13
2025-11-13
2025-11-13
2025-11-11
2025-11-11
2025-11-11
2024-11-15
2024-11-14
2024-11-01
2024-10-31
2024-10-30
2024-10-24
2024-10-22
2024-10-21
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-16
2024-10-15
2025-11-17
2025-09-17
2025-09-17
2025-09-17
2025-07-21
2025-02-05
2025-01-31
2025-01-31
2025-01-07
2025-01-07
2025-01-07
2025-01-07
2025-01-07
2025-01-07
2025-01-07